카테터 관련 요로감염 치료 시장 - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2032년)

Catheter Associated Urinary Tract Infections Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032

US $ 4,995 ￦ 7,057,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 12,003,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,977,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 카테터 관련 요로감염(CAUTI) 치료 시장은 치료 방법의 발전, 혁신적인 약물 처방, 감염 예방에 대한 인식이 높아짐에 따라 크게 성장할 것으로 예상됩니다. 의료 환경에서 흔히 발생하는 합병증인 CAUTI는 요도 카테터 사용과 관련된 세균 감염을 관리하고 예방하기 위해 표적화된 치료 개입이 필요합니다.

시장 인사이트

CAUTI 치료 시장 규모는 2025년까지 15억 달러에 달할 것으로 예상되며, 2032년까지 연평균 3.60%의 성장률로 19억 3,000만 달러로 확대될 것으로 전망됩니다. 이 시장의 성장 궤적은 의료 시설에서 요도 카테터의 보급에 따른 CAUTI 유병률 증가와 항생제 내성 우려의 증가에 영향을 받고 있습니다. 세계 카테터 관련 요로감염 치료 시장은 치료 기술의 발전과 감염 예방에 대한 관심 증가로 인해 큰 성장 잠재력을 가지고 있습니다. 주요 기업들은 연구개발에 대한 전략적 투자와 공동의 노력을 통해 진화하는 CAUTI 관리 문제를 해결하고 환자 결과를 개선하고 시장을 지속적으로 확대할 수 있도록 노력하고 있습니다. 또한, 재택의료와 원격의료의 부상은 접근이 용이하고 혁신적인 치료 솔루션의 중요성을 부각시키며 향후 몇 년 동안 혁신적인 헬스케어 분석의 길을 열어줄 것입니다.

세계 인구의 고령화로 인해 요도 카테터와 효과적인 감염 관리에 대한 수요가 증가하여 시장 성장을 촉진합니다. 혁신적인 항생제, 방부제 및 감염 방지 카테터 재료의 개발은 기존 치료법의 문제를 해결하고 환자 결과를 개선할 수 있습니다. 기존 항생제에 대한 내성이 증가함에 따라 항균 코팅 및 대체 약물 처방과 같은 새로운 치료 접근법이 등장하고 있습니다.

이 보고서는 세계 카테터 관련 요로감염증 치료 시장을 조사했으며, 시장 개요와 함께 약제 종류별, 적응증별, 유통 채널별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 정리하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나·러시아 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 카테터 관련 요로감염 치료 시장 전망, 2019-2032년

• 세계의 카테터 관련 요로감염 치료 시장 전망, 약물 유형별, 금액(10억 달러), 2019-2032년
• 세계의 카테터 관련 요로감염 치료 시장 전망, 적응증 유형별, 금액(10억 달러), 2019-2032년
• 세계의 카테터 관련 요로감염 치료 시장 전망, 유통 채널별, 금액(10억 달러), 2019-2032년
• 세계의 카테터 관련 요로감염 치료 시장 전망, 지역별, 금액(10억 달러), 2019-2032년

제4장 북미의 카테터 관련 요로감염 치료 시장 전망, 2019-2032년

제5장 유럽의 카테터 관련 요로감염 치료 시장 전망, 2019-2032년

제6장 아시아태평양의 카테터 관련 요로감염 치료 시장 전망, 2019-2032년

제7장 라틴아메리카의 카테터 관련 요로감염 치료 시장 전망, 2019-2032년

제8장 중동 및 아프리카의 카테터 관련 요로감염 치료 시장 전망, 2019-2032년

제9장 경쟁 구도

• 유통 채널별과 적응증 유형별 히트맵
• 제조업체별과 적응증 유형별 히트맵
• 기업 시장 점유율 분석, 2024년
• 경쟁 대시보드
• 기업 개요
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline(GSK)
  • AstraZeneca
  • Bayer AG
  • Johnson & Johnson
  • Novartis International AG
  • Sanofi
  • Roche Holding AG
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Boehringer Ingelheim
  • Daiichi Sankyo Company, Limited
  • Gilead Sciences, Inc.

제10장 부록

ksm

영문 목차

영문목차

The global catheter-associated urinary tract infections (CAUTIs) treatment market is poised for significant growth, driven by advancements in treatment modalities, innovative drug formulations, and increasing awareness of infection prevention. CAUTIs, a prevalent complication in healthcare settings, necessitate targeted therapeutic interventions to manage and prevent bacterial infections associated with urinary catheter use.

Market Insights

The CAUTIs treatment market is expected to reach a value of $1.50 billion by 2025 and expand further to $1.93 billion by 2032, registering a compound annual growth rate (CAGR) of 3.60%. The market's growth trajectory is influenced by the increasing prevalence of CAUTIs, driven by the widespread use of urinary catheters in healthcare facilities, and the rising concern of antibiotic resistance. The global catheter-associated urinary tract infections treatment market offers significant growth potential, driven by advancements in therapeutic technologies and a growing focus on infection prevention. With strategic investments in R&D and collaborative efforts, key players are poised to address the evolving challenges of CAUTI management, ensuring improved patient outcomes and sustained market expansion. Furthermore, the rise of home healthcare and telemedicine underscores the importance of accessible and innovative treatment solutions, paving the way for a transformative healthcare Analysis in the years ahead.

Key Market Drivers

• 1. Expanding Aging Population: The aging global population increases the demand for urinary catheters and effective infection management, boosting market growth.
• 2. Advancements in Treatment Modalities: The development of innovative antibiotics, antiseptics, and infection-resistant catheter materials addresses the challenges of traditional therapies and improves patient outcomes.
• 3. Antibiotic Resistance: The rising resistance to conventional antibiotics creates opportunities for novel therapeutic approaches, including antimicrobial coatings and alternative drug formulations.

Business Opportunities

• 1. Rise in Home Healthcare and Telemedicine: The growing trend of home healthcare and remote medical services calls for patient-friendly and self-administered treatment options for CAUTIs. These approaches address the unique needs of patients outside traditional healthcare settings, providing significant market potential.
• 2. Antimicrobial Coatings for Catheters: Technological advancements in catheters with controlled-release antimicrobial coatings present lucrative revenue opportunities, addressing both prevention and treatment needs. The integration of antimicrobial technologies in catheter design minimizes bacterial colonization risks, enhancing patient safety.
• 3. Collaborative Research: Partnerships between pharmaceutical companies, healthcare providers, and research institutions drive innovation in CAUTI treatments, enhancing market dynamics. These collaborations foster the development of advanced therapeutic solutions tailored to emerging healthcare challenges.

Regional Analysis

• Europe: Dominates the market due to advanced healthcare infrastructure, robust research initiatives, and strategic collaborations that drive innovation. Regulatory support and funding for infection control further bolster Europe's market leadership.
• South Asia & Pacific: Emerges as the fastest-growing region, fueled by population expansion, increasing awareness, and evolving healthcare infrastructure. The adoption of modern healthcare practices and government-backed programs support market growth in this region.
• North America: Maintains a strong market presence owing to well-established healthcare systems and significant investment in medical research. The region's focus on technological integration enhances CAUTI treatment strategies.

Key Players

Prominent companies shaping the CAUTIs treatment market include:

• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline (GSK)
• AstraZeneca
• Bayer AG
• Johnson & Johnson
• Novartis International AG
• Sanofi
• Roche Holding AG
• Abbott Laboratories
• Bristol-Myers Squibb Company
• Astellas Pharma Inc.
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.

Market Segmentation

1. By Drug Type:

Penicillin & Combinations Quinolones Cephalosporins Aminoglycoside Antibiotics Sulphonamides Azoles and Amphotericin B Tetracycline Nitrofurantoin

2. By Indication Type:

Asymptomatic CAUTI (Bacteriuria) Symptomatic CAUTI (Bacteremic)

3. By Distribution Channel:

Hospital Pharmacies Gynecology and Urology Clinics Drug Stores Retail Pharmacies Online Drug Stores

4. By Region:

North America Europe Asia Pacific Latin America Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Catheter Associated Urinary Tract Infections Treatment Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2024
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

• 3.1. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
  • 3.1.1. Key Highlights
    • 3.1.1.1. Penicillin & Combinations
    • 3.1.1.2. Quinolones
    • 3.1.1.3. Caphalosporin
    • 3.1.1.4. Aminoglycoside Antibiotics
    • 3.1.1.5. Sulphonamides
    • 3.1.1.6. Azoles and Amphotericin B
    • 3.1.1.7. Tetracycline
    • 3.1.1.8. Nitrofura
• 3.2. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
  • 3.2.1. Key Highlights
    • 3.2.1.1. Asymptomatic CAUTI (Bacteriuria)
    • 3.2.1.2. Symptomatic CAUTI (Bacteremic)
• 3.3. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
  • 3.3.1. Key Highlights
    • 3.3.1.1. Hospital Pharmacies
    • 3.3.1.2. Gynaecology and Urology Clinics
    • 3.3.1.3. Drug Stores
    • 3.3.1.4. Retail Pharmacies
    • 3.3.1.5. Online Drug Stores
• 3.4. Global Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
  • 3.4.1. Key Highlights
    • 3.4.1.1. North America
    • 3.4.1.2. Europe
    • 3.4.1.3. Asia Pacific
    • 3.4.1.4. Latin America
    • 3.4.1.5. Middle East & Africa

4. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

• 4.1. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
  • 4.1.1. Key Highlights
    • 4.1.1.1. Penicillin & Combinations
    • 4.1.1.2. Quinolones
    • 4.1.1.3. Cephalosporin
    • 4.1.1.4. Aminoglycoside Antibiotics
    • 4.1.1.5. Sulphonamides
    • 4.1.1.6. Azoles and Amphotericin B
    • 4.1.1.7. Tetracycline
    • 4.1.1.8. Nitrofura
• 4.2. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
  • 4.2.1. Key Highlights
    • 4.2.1.1. Asymptomatic CAUTI (Bacteriuria)
    • 4.2.1.2. Symptomatic CAUTI (Bacteremic)
• 4.3. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
  • 4.3.1. Key Highlights
    • 4.3.1.1. Hospital Pharmacies
    • 4.3.1.2. Gynaecology and Urology Clinics
    • 4.3.1.3. Drug Stores
    • 4.3.1.4. Retail Pharmacies
    • 4.3.1.5. Online Drug Stores
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis
• 4.4. North America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 4.4.1. Key Highlights
    • 4.4.1.1. U.S. Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 4.4.1.2. U.S. Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 4.4.1.3. U.S. Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.4.1.4. Canada Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 4.4.1.5. Canada Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 4.4.1.6. Canada Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
  • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

• 5.1. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
  • 5.1.1. Key Highlights
    • 5.1.1.1. Penicillin & Combinations
    • 5.1.1.2. Quinolones
    • 5.1.1.3. Cephalosporin
    • 5.1.1.4. Aminoglycoside Antibiotics
    • 5.1.1.5. Sulphonamides
    • 5.1.1.6. Azoles and Amphotericin B
    • 5.1.1.7. Tetracycline
    • 5.1.1.8. Nitrofura
• 5.2. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
  • 5.2.1. Key Highlights
    • 5.2.1.1. Asymptomatic CAUTI (Bacteriuria)
    • 5.2.1.2. Symptomatic CAUTI (Bacteremic)
• 5.3. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
  • 5.3.1. Key Highlights
    • 5.3.1.1. Hospital Pharmacies
    • 5.3.1.2. Gynaecology and Urology Clinics
    • 5.3.1.3. Drug Stores
    • 5.3.1.4. Retail Pharmacies
    • 5.3.1.5. Online Drug Stores
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis
• 5.4. Europe Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 5.4.1. Key Highlights
    • 5.4.1.1. Germany Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.2. Germany Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.3. Germany Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.4.1.4. U.K. Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.5. U.K. Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.6. U.K. Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.4.1.7. France Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.8. France Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.9. France Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.4.1.10. Italy Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.11. Italy Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.12. Italy Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.4.1.13. Turkey Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.14. Turkey Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.15. Turkey Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.4.1.16. Russia Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.17. Russia Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.18. Russia Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.4.1.19. Rest of Europe Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.20. Rest of Europe Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.21. Rest of Europe Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
  • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

• 6.1. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
  • 6.1.1. Key Highlights
    • 6.1.1.1. Penicillin & Combinations
    • 6.1.1.2. Quinolones
    • 6.1.1.3. Cephalosporin
    • 6.1.1.4. Aminoglycoside Antibiotics
    • 6.1.1.5. Sulphonamides
    • 6.1.1.6. Azoles and Amphotericin B
    • 6.1.1.7. Tetracycline
    • 6.1.1.8. Nitrofura
• 6.2. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
  • 6.2.1. Key Highlights
    • 6.2.1.1. Asymptomatic CAUTI (Bacteriuria)
    • 6.2.1.2. Symptomatic CAUTI (Bacteremic)
• 6.3. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
  • 6.3.1. Key Highlights
    • 6.3.1.1. Hospital Pharmacies
    • 6.3.1.2. Gynaecology and Urology Clinics
    • 6.3.1.3. Drug Stores
    • 6.3.1.4. Retail Pharmacies
    • 6.3.1.5. Online Drug Stores
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis
• 6.4. Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 6.4.1. Key Highlights
    • 6.4.1.1. China Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.2. China Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.3. China Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.4.1.4. Japan Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.5. Japan Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.6. Japan Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.4.1.7. South Korea Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.8. South Korea Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.9. South Korea Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.4.1.10. India Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.11. India Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.12. India Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.4.1.13. Southeast Asia Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.14. Southeast Asia Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.15. Southeast Asia Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.4.1.16. Rest of Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.17. Rest of Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.18. Rest of Asia Pacific Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
  • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

• 7.1. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
  • 7.1.1. Key Highlights
    • 7.1.1.1. Penicillin & Combinations
    • 7.1.1.2. Quinolones
    • 7.1.1.3. Cephalosporin
    • 7.1.1.4. Aminoglycoside Antibiotics
    • 7.1.1.5. Sulphonamides
    • 7.1.1.6. Azoles and Amphotericin B
    • 7.1.1.7. Tetracycline
    • 7.1.1.8. Nitrofura
• 7.2. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
  • 7.2.1.1. Asymptomatic CAUTI (Bacteriuria)
  • 7.2.1.2. Symptomatic CAUTI (Bacteremic)
• 7.3. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
  • 7.3.1. Key Highlights
    • 7.3.1.1. Hospital Pharmacies
    • 7.3.1.2. Gynaecology and Urology Clinics
    • 7.3.1.3. Drug Stores
    • 7.3.1.4. Retail Pharmacies
    • 7.3.1.5. Online Drug Stores
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis
• 7.4. Latin America Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 7.4.1. Key Highlights
    • 7.4.1.1. Brazil Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.2. Brazil Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.3. Brazil Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.4.1.4. Mexico Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.5. Mexico Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.6. Mexico Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.4.1.7. Argentina Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.8. Argentina Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.9. Argentina Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.4.1.10. Rest of Latin America Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.11. Rest of Latin America Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.12. Rest of Latin America Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
  • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, 2019 - 2032

• 8.1. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019 - 2032
  • 8.1.1. Key Highlights
    • 8.1.1.1. Penicillin & Combinations
    • 8.1.1.2. Quinolones
    • 8.1.1.3. Cephalosporin
    • 8.1.1.4. Aminoglycoside Antibiotics
    • 8.1.1.5. Sulphonamides
    • 8.1.1.6. Azoles and Amphotericin B
    • 8.1.1.7. Tetracycline
    • 8.1.1.8. Nitrofura
• 8.2. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Indication Type, Value (US$ Bn), 2019 - 2032
  • 8.2.1. Key Highlights
    • 8.2.1.1. Asymptomatic CAUTI (Bacteriuria)
    • 8.2.1.2. Symptomatic CAUTI (Bacteremic)
• 8.3. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
  • 8.3.1. Key Highlights
    • 8.3.1.1. Hospital Pharmacies
    • 8.3.1.2. Gynaecology and Urology Clinics
    • 8.3.1.3. Drug Stores
    • 8.3.1.4. Retail Pharmacies
    • 8.3.1.5. Online Drug Stores
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis
• 8.4. Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 8.4.1. Key Highlights
    • 8.4.1.1. GCC Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.2. GCC Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.3. GCC Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.4.1.4. South Africa Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.5. South Africa Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.6. South Africa Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.4.1.7. Egypt Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.8. Egypt Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.9. Egypt Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.4.1.10. Nigeria Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.11. Nigeria Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.12. Nigeria Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.4.1.13. Rest of Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market by Drug Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.14. Rest of Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market by Indication Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.15. Rest of Middle East & Africa Catheter Associated Urinary Tract Infections Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
  • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. By Distribution Channel vs by Indication Type Heat map
• 9.2. Manufacturer vs by Indication Type Heatmap
• 9.3. Company Market Share Analysis, 2024
• 9.4. Competitive Dashboard
• 9.5. Company Profiles
  • 9.5.1. Pfizer Inc.
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Product Portfolio
    • 9.5.1.3. Financial Overview
    • 9.5.1.4. Business Strategies and Development
  • 9.5.2. Merck & Co., Inc.
  • 9.5.3. GlaxoSmithKline (GSK)
  • 9.5.4. AstraZeneca
  • 9.5.5. Bayer AG
  • 9.5.6. Johnson & Johnson
  • 9.5.7. Novartis International AG
  • 9.5.8. Sanofi
  • 9.5.9. Roche Holding AG
  • 9.5.10. Eli Lilly and Company
  • 9.5.11. Bristol-Myers Squibb Company
  • 9.5.12. Abbott Laboratories
  • 9.5.13. Astellas Pharma Inc.
  • 9.5.14. Boehringer Ingelheim
  • 9.5.15. Daiichi Sankyo Company, Limited
  • 9.5.16. Gilead Sciences, Inc.

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료